Muna Therapeutics ApS has patented triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus ...

Like waves crashing on the beach, med-tech IPOs keep on coming. Heartflow Inc. set terms for its IPO on Aug. 1, offering 12.5 ...

Sava Technologies Ltd. raised $19 million in a series A funding round for its multi-molecule biosensor platform that can detect biomarkers just beneath the skin, in real-time. The funds will go ...

While U.S. President Donald Trump’s country-by-country reciprocal and newly negotiated tariffs go into effect today, a separate, global biopharma sector tariff of, possibly, 200% continues to loom ...

With the U.S. FDA’s approval of Lenz Therapeutics Inc.’s Vizz (aceclidine ophthalmic solution), there is a third eye drop on ...

Nonprofit dealmaking in biopharma has been limited in 2025, with total disclosed value reaching just $99.7 million through ...

The U.S. Department of Justice announced July 31 that Illumina Inc. agreed to pay $9.8 million to settle allegations it sold ...

GSK plc scientists have presented findings from studies on the therapeutic potential of GSK-5862611, an anti-Sortilin ...

Regeneron Pharmaceuticals Inc. disclosed within a positive second-quarter earnings report that it had received a complete response letter (CRL) two days earlier from the U.S. FDA for its bispecific ...

The U.K. quoted biotech investment firm Syncona plc is facing into the volatile market conditions and the impact U.S. trade policy, regulatory uncertainty and pharma pricing are having on access to ...

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...

Bristol Myers Squibb Co. has prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 ...